Business
Satellos Bioscience Inc.'s CSO to Present Game Changing Science During March 30th Drug Discovery News Webinar
Michael Rudnicki, PhD and Chief Scientific Officer to highlight new advancements with Satellos...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Inc.'s CSO to Present Game Changing Science During March 30th Drug Discovery News WebinarMichael Rudnicki, PhD and Chief Scientific Officer to highlight new advancements with Satellos' novel muscle regeneration technology on March 30Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\"), a biotechnology company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Michael Rudnicki, PhD, Senior Scientist and Director of the Regenerative Medicine Program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute will be presenting at an upcoming Drug Discovery News webinar on stem cell research scheduled for March 30, 2022.Titled, \"The Promise and Reality of Stem Cell Research,\" the 90-minute event will begin at 11:30 AM ET and feature presentations from Dr. Rudnicki and Evan Snyder, MD, PhD, Professor, Human Genetics Program and Director of the Center for Stem Cells and Regenerative Medicine with the Sanford Burnham Prebys Medical Discovery Institute. A 30-minute live Q&A with the audience will follow. Registration for the event can be found here. In his presentation, Dr. Rudnicki will highlight the foundational discoveries his laboratory has made into the role muscle stem cells play in regeneration and the efforts being undertaken at Satellos to translate these discoveries into novel therapeutic treatments. Dr. Rudnicki's lab was first to characterize muscle stem cells and identify how deficits in \"polarity\", the process by which they divide to repair and regenerate muscle, are causal factors in the chronic degeneration seen in Duchenne muscular dystrophy (\"Duchenne\"), a fatal genetic disease. His pioneering work affords renewed hope for a disease modifying treatment approach in Duchenne and potentially other devastating muscle disorders. \"We look forward to our Co-founder and Chief Scientific Officer, Dr. Michael Rudnicki, discussing his important research and its therapeutic potential alongside other leaders and guests who are as passionate about the potential for stem cell treatments to drastically improve the lives of patients as we are,\" said Satellos Co-founder and CEO, Frank Gleeson. \"At Satellos, we are developing first-in-class oral drugs which ...